Want to join the conversation?
Obesity drug developer $OREX's revenue tumbled to $10MM from $30.8MM in 3Q14. The reported revenue for the quarter includes $2.6MM in royalties earned on U.S. net sales of Contrave of $12.8MM recorded by $OREX's partner Takeda Pharmaceuticals.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?